Objective: To investigate the value of combined application of compound Kushen injection and cisplatin intraperitoneal chemotherapy in patients with gastric cancer and malignant ascites. Method: The 96 patients with gastric cancer and malignant ascites in our hospital from January 2012 to December 2013 were selected and divided into study group and control group with random number table method

48 cases in each group. Patients with gastric cancer and malignant ascites in study group were treated with compound Kushen injection combined with cisplatin intraperitoneal chemotherapy

while patients with gastric cancer and malignant ascites in control group were treated with cisplatin intraperitoneal chemotherapy only. The clinical treatment conditions of patients in two groups were compared and analyzed. Result: As compared with the control group

the ratio of partial remission and total effective rate were increased in the patients with gastric cancer in study group

with significant differences (P < 0.05)

the improvement ratio of life quality was increased in the study group

with statistically significant differences (P < 0.05)

the ratio of reduction was increased

with highly statistically significant difference (P < 0.01)

NK cells and CD3+ cell were increased significantly

with statistically significant differences (P < 0.05)

CD4+ cell and CD4+/CD8+ were increased significantly

while CD8+ cell was reduced significantly

with highly statistically significant differences(P < 0.01)

the overall incidence of adverse reactions was significantly lower than that in control group

with highly statistically significant difference (P < 0.01). Conclusion: Compound Kushen injection combined with cisplatin intraperitoneal chemotherapy had extremely important practical significance in improving the clinical efficacy

improving quality of life

enhancing immunity

and reducing the adverse reactions for patients with gastric cancer and malignant ascites.